Search

• 

  Fresh insights could finally help us tackle RSV

  Behind the science magazine

  The 60 year search for solutions for RSV

  https://www.gsk.com/en-gb/behind-the-science-magazine/fresh-insights-could-finally-help-us-tackle-rsv/

  First published: 11 February 2022

• Vir Biotechnology and GSK provide update on NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19

  Media

  The DSMB has recommended that the VIR-7831 arm of the trial be closed to enrolment while the data mature.

  https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-provide-update-on-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/

  First published: 03 March 2021

• 

  Back to school immunity: vaccination catch-ups are needed to stop the escalation of preventable diseases in children

  Behind the science magazine

  Medical experts say now is the time to catch up on essential immunisation programs to ensure young people and communities are protected

  https://www.gsk.com/en-gb/behind-the-science-magazine/child-immunity-gap-vaccination-catch-up/

  First published: 12 September 2023

• 

  Health security

  Responsibility

  At GSK, we’re uniting science, technology and talent to get ahead of health security threats

  https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/health-security/

  First published: 18 March 2024

• GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders

  Media

  GSK announces a major conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses

  https://www.gsk.com/en-gb/media/press-releases/gsk-plc-announces-major-three-part-transaction-with-novartis-to-drive-sustainable-sales-growth-improve-long-term-earnings-and-deliver-increasing-returns-to-shareholders/

  First published: 22 April 2014

• Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment

  Media

  Phase 2/3 study will investigate the safety and efficacy of antibody treatment in preventing hospitalisation due to COVID-19.

  https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-start-phase-23-study-of-covid-19-antibody-treatment/

  First published: 31 August 2020

• Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19

  Media

  Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19

  https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-vir-7831-reduces-hospitalisation-and-risk-of-death-in-early-treatment-of-adults-with-covid-19/

  First published: 10 March 2021

• GSK and Vir Biotechnology announce submission of Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19

  Media

  The FDA EUA submission is based on an interim analysis of efficacy and safety data from the Phase 3 COMET-ICE trial.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-submission-of-emergency-use-authorization-request-to-fda-for-vir-7831-for-the-early-treatment-of-covid-19/

  First published: 26 March 2021

• GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19

  Media

  GSK and Vir continue discussions with global regulators to make VIR-7831 available to patients with COVID-19.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-ema-review-of-dual-action-monoclonal-antibody-vir-7831-for-the-early-treatment-of-covid-19/

  First published: 15 April 2021

• EMA issues positive scientific opinion on GSK and Vir Biotechnology’s sotrovimab for the early treatment of COVID-19

  Media

  Opinion based on the EMA’s CHMP review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19.

  https://www.gsk.com/en-gb/media/press-releases/ema-issues-positive-scientific-opinion-on-gsk-and-vir-biotechnology-s-sotrovimab-for-the-early-treatment-of-covid-19/

  First published: 21 May 2021